A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-02-25
AEs
3
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-28 (study day 145); relationship: not assessed
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 179); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-28 (study day 388); relationship: not assessed
Data queries
No data queries.